The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented new data highlighting the accuracy the G7 in children at last month’s Advanced Technologies & Treatments for Diabetes (ATTD) conference.
Dexcom Chief Technology Officer Jake Leach recently told Drug Delivery Business News that, while the excitement around G7 remains, that’s far from the only thing the San Diego-based company has to offer.
Get the full story at our sister site, Drug Delivery Business News.